Disease & disorder

interstitial lung disease

MONDO:0015925

A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of pulmonary alveoli that extends to the interstitium and beyond leading to diffuse pulmonary fibrosis. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.

Clinical trials135
Recruiting35
Drug concepts studied15
Synonyms2

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Interstitial lung disease

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium (the tissue) and space around the alveoli (air sacs) of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. While many forms are progressive and serious, some types of ILD remain mild or stable for extended periods, especially with early detection and appropriate treatment. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases. There are specific types in children, known as children's interstitial lung diseases. The acronym ChILD is sometimes used for this group of diseases. In children, the pathophysiology involves a genetic component, exposure-related injury, autoimmune dysregulation, or all of the components. Thirty to 40% of those with interstitial lung disease eventually develop p...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

40 shown
Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT ImagingNCT07613099 · 2026-09-18
RECRUITING
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)NCT07816185 · 2026-08-31
RECRUITING
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07234032 · 2026-07-20
RECRUITING
The Benefits of Home Exercise in Pulmonary Hypertension Interstitial Lung DiseaseNCT07561034 · 2026-07-15
RECRUITING
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung DiseaseNCT07843381 · 2026-05-01
RECRUITING
Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional HypoxemiaNCT07451977 · 2026-04-02
RECRUITING
Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension TreatmentNCT07254338 · 2026-02-16
RECRUITING
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT07179380 · 2026-01-07
RECRUITING
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung DiseaseNCT07323732 · 2026-01-06
RECRUITING
Generative AI Impact on Rheumatoid Arthritis Complications DiagnosisNCT07301892 · 2025-10-01
RECRUITING
SWEEP: Shuttle Walking Test for Exercise Evaluation in Pulmonary ResectionNCT07102589 · 2025-06-01
RECRUITING
Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary DiseasesNCT06983366 · 2025-05-30
RECRUITING
The Use of Entropy to Assess Sleep Disordered Breathing in Chronic Respiratory DiseaseNCT07060079 · 2025-04-30
RECRUITING
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)NCT06388421 · 2025-01-23
RECRUITING
Reducing Respiratory Symptoms of Pulmonary Irradiation in Interstitial Lung DiseaseNCT05986318 · 2025-01-07
RECRUITING
dEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasoundNCT06235645 · 2024-11-18
RECRUITING
Impact of Remote Vital Signs Monitoring in People Using Long-term Oxygen TherapyNCT06882265 · 2024-11-10
RECRUITING
Reducing Chronic Breathlessness in Adults by Following a Self-guided, Internet Based Supportive Intervention (SELF-BREATHE)NCT06326957 · 2024-07-04
RECRUITING
Identification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled BreathNCT06528418 · 2024-06-30
RECRUITING
Effect of HIgh-flow Therapy in Long-term Oxygen TherapyNCT06247397 · 2024-06-10
RECRUITING
The Effect of Exercise Training on lncRNA Expression in Rheumatoid ArthritisNCT07320846 · 2024-05-18
RECRUITING
Taiwan Interstitial Lung Disease Multi-center Investigation and RegistryNCT06476470 · 2024-03-10
RECRUITING
Feasibility of Semaglutide in Advanced Lung DiseaseNCT05746039 · 2024-01-29
RECRUITING
Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung DiseaseNCT06397677 · 2024-01-22
RECRUITING
129Xe MRI CardiopulmonaryNCT06038630 · 2024-01-12
RECRUITING
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PHNCT06129240 · 2023-12-28
RECRUITING
Pulmonary Hypertension SOLARNCT04778046 · 2023-11-08
RECRUITING
Ultrasound and Respiratory Physiological Signals in Lung DiseasesNCT06068647 · 2023-03-22
RECRUITING
Evaluate the Effect of Dietary Supplement Combined Exercise Among Patients With Sarcopenia Comorbid With Lung DiseaseNCT05926713 · 2023-03-01
RECRUITING
Practice of Oxygenation and Respiratory Support During Fiberoptic BronchoscopyNCT05681962 · 2023-02-15
RECRUITING
Sarcopenia in Chronic Lung DiseasesNCT06280443 · 2022-11-25
RECRUITING
Screening of Patients With Rheumatoid Arthritis for Interstitial Lung DiseaseNCT05391100 · 2022-02-01
RECRUITING
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary DiseaseNCT04624490 · 2020-11-02
RECRUITING
Autologous Stem Cell Transplantation in Patients With Systemic SclerosisNCT03630211 · 2018-07-31
RECRUITING
Rheumatoid Arthritis Patients at Risk for Interstitial Lung DiseaseNCT03297775 · 2017-06-22
RECRUITING
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic SclerosisNCT07821398 · 2026-11-01
NOT_YET_RECRUITING
Titrated Ambulatory Oxygen in Fibrotic ILD and COPD With Isolated Exertional HypoxemiaNCT07512687 · 2026-09-02
ENROLLING_BY_INVITATION
Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPDNCT07714252 · 2026-08-06
ENROLLING_BY_INVITATION
Lung Cancer Screening CT for FirefightersNCT06836414 · 2026-03-31
WITHDRAWN
MOBoxy: MoblO2 to Maintain OxygenationNCT07222592 · 2025-12-01
NOT_YET_RECRUITING

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.